Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Total Non-Current Liabilities (2018 - 2026)

Profound Medical has reported Total Non-Current Liabilities over the past 6 years, most recently at $11.0 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 12.53% year-over-year to $11.0 million; the TTM value through Dec 2025 reached $11.0 million, up 12.53%, while the annual FY2025 figure was $11.0 million, 12.53% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $11.0 million at Profound Medical, up from $10.1 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $12.7 million in Q4 2023 and troughed at $9.7 million in Q4 2024.
  • A 3-year average of $10.8 million and a median of $10.7 million in 2024 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: decreased 23.05% in 2024 and later rose 12.53% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $12.7 million in 2023, then dropped by 23.05% to $9.7 million in 2024, then rose by 12.53% to $11.0 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for PROF at $11.0 million in Q4 2025, $10.1 million in Q3 2025, and $10.3 million in Q2 2025.